PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 14515361-0 2003 Cycloheximide and actinomycin D delay death and affect bcl-2, bax, and Ice gene expression in astrocytes under in vitro ischemia. Cycloheximide 0-13 BCL2 apoptosis regulator Homo sapiens 55-60 14515361-12 2003 The data suggest that the ratio of Bcl-2/Bad in astrocytes following ActD and CHX treatment does not decrease as much in untreated cells during ischemia. Cycloheximide 78-81 BCL2 apoptosis regulator Homo sapiens 35-40 12212968-4 2002 The administration of agonistic anti-Fas antibody (CH-11) or cycloheximide alone did not induce apoptosis, whereas the co-administration of CH-11 with cycloheximide induced apoptosis in WI-38 cells, in which caspase-8 and -3, but not -9, were activated, and X chromosome-linked inhibitor of apoptosis (ILP) and FLICE-like inhibitor protein (FLIP(L)), but not bcl-xL and bcl-2, were remarkably down regulated. Cycloheximide 151-164 BCL2 apoptosis regulator Homo sapiens 370-375 12421372-2 2002 This cell death can be blocked by genetic deletion of Bax, a member of the pro-apoptotic Bcl-2 family, cycloheximide an inhibitor of macromolecular synthesis or expression of dominant-negative c-jun. Cycloheximide 103-116 BCL2 apoptosis regulator Homo sapiens 89-94 2771409-5 1989 However, in the presence of cycloheximide (inhibitor of protein synthesis), the half-life of some of the bcl-2/Ig mRNAs produced by these cells was prolonged, indicating that in some circumstances mRNA stability may contribute to deregulated bcl-2 expression. Cycloheximide 28-41 BCL2 apoptosis regulator Homo sapiens 105-110 11726273-3 2001 Phosphorylation is effectively inhibited in the presence of actinomycin D or cycloheximide, which restore cell viability to the same level as control cells not expressing Bcl-2. Cycloheximide 77-90 BCL2 apoptosis regulator Homo sapiens 171-176 10506215-12 1999 Furthermore, adenovirus-mediated delivery of an IkappaBalpha mutant to prevent NFkappaB activation impaired the ability of Bcl-2 to suppress apoptosis provoked by TNFalpha plus cycloheximide in ventricular myocytes. Cycloheximide 177-190 BCL2 apoptosis regulator Homo sapiens 123-128 10381626-5 1999 Exposure of TPA-differentiated U937 cells to 0.8 microg/ml cycloheximide for 24 h, that triggers apoptosis in 50% cells, activates procaspase-2L, -3 and -8, induces the mitochondrial release of cytochrome c and decreases Bcl-xL expression without modifying Bcl-2, Mcl-1 and Bax protein levels. Cycloheximide 59-72 BCL2 apoptosis regulator Homo sapiens 257-262 9396780-7 1997 Western analysis of Bcl-2 protein obtained from overexpressing cells treated with bryostatin 1, staurosporine, or UCN-01 revealed the appearance of a slowly migrating species and a general broadening of the protein band, effects that were insensitive to the protein synthesis inhibitor cycloheximide. Cycloheximide 286-299 BCL2 apoptosis regulator Homo sapiens 20-25 8814273-5 1996 Burkitt lymphoma (BL)-derived, Bcl-2- B cells were induced into apoptosis either by the Ca(2+)-ionophore ionomycin or by the inhibitor of protein synthesis cycloheximide. Cycloheximide 156-169 BCL2 apoptosis regulator Homo sapiens 31-36 11329613-7 2001 Actually, cycloheximide alone was able to induce hepatoma cell BEL7404 to death that could also be inhibited by over-expressing Bcl-2. Cycloheximide 10-23 BCL2 apoptosis regulator Homo sapiens 128-133 10554162-8 1999 Enhanced Bcl-2 expression was inhibited by cycloheximide, actinomycin D, or antisense oligonucleotide directed against bcl-2 mRNA. Cycloheximide 43-56 BCL2 apoptosis regulator Homo sapiens 9-14 8663307-4 1996 In this work, we examined the effect of BCL-2 overexpression on acidification mediated by cycloheximide treatment or Fas ligation in Jurkat T-lymphoblasts. Cycloheximide 90-103 BCL2 apoptosis regulator Homo sapiens 40-45 7669718-6 1995 Another myeloid leukemia that shows barely detectable expression of bcl-2 also showed up-regulated expression of bcl-XL but no change in bax after induction of differentiation with granulocyte-macrophage colony-stimulating factor, and this reduced cell susceptibility to induction of apoptosis by Adriamycin or cycloheximide. Cycloheximide 311-324 BCL2 apoptosis regulator Homo sapiens 68-73 7539458-5 1995 Forced expression of bcl-2 also attenuated TNF alpha-mediated cytotoxicity of glioma cell lines in the presence of actinomycin D and cycloheximide and conferred partial protection from irradiation and the cancer chemotherapy drugs, cisplatin and BCNU. Cycloheximide 133-146 BCL2 apoptosis regulator Homo sapiens 21-26 34303041-6 2021 Additionally, BAY11-7082, actinomycin D, and cycloheximide have inhibitory effects on As2O3-induced expression of BCL-2 mRNA and protein, and restore the cell viability of BEAS-2B cells. Cycloheximide 45-58 BCL2 apoptosis regulator Homo sapiens 114-119 2771409-5 1989 However, in the presence of cycloheximide (inhibitor of protein synthesis), the half-life of some of the bcl-2/Ig mRNAs produced by these cells was prolonged, indicating that in some circumstances mRNA stability may contribute to deregulated bcl-2 expression. Cycloheximide 28-41 BCL2 apoptosis regulator Homo sapiens 242-247 2771409-6 1989 Despite stabilizing some bcl-2 mRNAs, the overall effect of treating cell lines with cycloheximide was a reduction in the levels of accumulated bcl-2 mRNAs through inhibition of bcl-2 gene transcription. Cycloheximide 85-98 BCL2 apoptosis regulator Homo sapiens 25-30 2771409-6 1989 Despite stabilizing some bcl-2 mRNAs, the overall effect of treating cell lines with cycloheximide was a reduction in the levels of accumulated bcl-2 mRNAs through inhibition of bcl-2 gene transcription. Cycloheximide 85-98 BCL2 apoptosis regulator Homo sapiens 144-149 2771409-6 1989 Despite stabilizing some bcl-2 mRNAs, the overall effect of treating cell lines with cycloheximide was a reduction in the levels of accumulated bcl-2 mRNAs through inhibition of bcl-2 gene transcription. Cycloheximide 85-98 BCL2 apoptosis regulator Homo sapiens 144-149 21618512-5 2012 Cisplatin-mediated increase in Bcl-2 expression was blocked by combination with either actinomycin D or cycloheximide. Cycloheximide 104-117 BCL2 apoptosis regulator Homo sapiens 31-36 19151744-5 2009 The mechanism by which BAG-1 affected the function of Bcl-2 was exploredby using the cycloheximide chase assay. Cycloheximide 85-98 BCL2 apoptosis regulator Homo sapiens 54-59 19151744-11 2009 Furthermore, the cycloheximide chase assay indicated that the degradation of Bcl-2 protein was extended in the BAG-1 p50 and p46 transfected MCF-7 cells. Cycloheximide 17-30 BCL2 apoptosis regulator Homo sapiens 77-82 26622397-10 2015 In addition, examination of cytoplasmic vacuolization using microscopy indicated that there were a small number of paraptosis cells present at 24 h. The expression levels of Bcl-2 was significantly decreased, while Bax was significantly increased at 48 h. Furthermore, cycloheximide treatment was demonstrated to significantly increase Bcl-2 expression, while decreasing Bax expression (P>0.05). Cycloheximide 269-282 BCL2 apoptosis regulator Homo sapiens 174-179